Cronos Group (CRON) vs. Its Peers Financial Analysis

Cronos Group (NASDAQ: CRON) is one of 33 public companies in the “Medicinals & botanicals” industry, but how does it compare to its rivals? We will compare Cronos Group to related businesses based on the strength of its dividends, risk, valuation, institutional ownership, earnings, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for Cronos Group and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group 1 4 4 0 2.33
Cronos Group Competitors 136 360 408 14 2.33

Cronos Group presently has a consensus target price of $9.83, indicating a potential upside of 66.95%. As a group, “Medicinals & botanicals” companies have a potential upside of 86.68%. Given Cronos Group’s rivals higher possible upside, analysts plainly believe Cronos Group has less favorable growth aspects than its rivals.

Valuation and Earnings

This table compares Cronos Group and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cronos Group $25.64 million $1.17 billion 8.79
Cronos Group Competitors $218.50 million -$99.79 million -1.87

Cronos Group’s rivals have higher revenue, but lower earnings than Cronos Group. Cronos Group is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Cronos Group and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cronos Group 1,729.07% -2.57% -2.17%
Cronos Group Competitors -163.69% -267.59% -46.37%

Insider and Institutional Ownership

12.1% of Cronos Group shares are held by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 7.9% of Cronos Group shares are held by insiders. Comparatively, 25.8% of shares of all “Medicinals & botanicals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Cronos Group has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Comparatively, Cronos Group’s rivals have a beta of 2.56, meaning that their average stock price is 156% more volatile than the S&P 500.

About Cronos Group

Cronos Group Inc. operates as a cannabinoid company in the United States and internationally. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through ecommerce, retail, and hospitality partner channels. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. Its brand portfolio includes PEACE NATURALS, a global wellness platform; adult-use brands comprise COVE and Spinach; and hemp-derived CBD brands consists of Lord Jones and PEACE+. Cronos Group Inc. is based in Toronto, Canada.

Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.